CDKN2B-AS1 and hepatocellular carcinoma: Such mechanisms have been already reported in various contexts, including HCC, where ANRIL enhances cancer migration and proliferation by modulating the expression of the miR-191 and by subsequently affecting the vimentin expression [260].